B Cell-Targeted and Autoantibody-Modulating Strategies
1 Bruton’s Tyrosine Kinase (BTK) Inhibition
(Certainty: 0.35.) If IgM-dominant tissue-specific autoantibodies arise from ongoing extrafollicular BCR signaling — as suggested by the IgM persistence (60% vs 36% in controls, 141-day follow-up) in long COVID (Tatai et al. 2026) — BTK inhibition could suppress new autoantibody production. BTK (Bruton’s tyrosine kinase) is critical for BCR signal transduction; BTK inhibitors (ibrutinib, acalabrutinib) are approved for B cell malignancies with demonstrated autoantibody reduction in rheumatoid arthritis and lupus.
Combination rationale: BTK inhibition suppresses new autoantibody production; immunoadsorption clears existing circulating antibodies. The combination targets both production and removal — BTK inhibitor stops new IgM synthesis, while IA clears the existing pool. This is mechanistically analogous to “induction + maintenance” in oncology.
Safety: BTK inhibitors carry infection risk (sinopulmonary) and cardiac toxicity (atrial fibrillation, hypertension). Risk-benefit for a non-malignant indication requires careful evaluation in trials with prespecified safety endpoints. No human data in ME/CFS.
Falsifiable prediction: Acalabrutinib 100 mg daily for 12 weeks reduces total IgM and tissue-specific IgM autoantibody titers by \(\geq 30%\) in ME/CFS patients with IgM-dominant profiles. Combined BTK inhibition + IA produces greater and more sustained autoantibody reduction than IA alone (\(\geq 60%\) vs \(\sim 30%\) at 6 months). (Tatai et al. 2026).
2 BAFF Inhibition (Belimumab)
(Certainty: 0.30.) BAFF (B-cell activating factor) promotes B cell survival and is required for extrafollicular plasmablast differentiation. Belimumab (anti-BAFF monoclonal antibody, approved for SLE) reduces autoantibody production by depleting BAFF-dependent transitional and naive B cells. If ME/CFS involves BAFF-driven autoantibody persistence — supported by elevated BAFF in some ME/CFS studies — belimumab could reduce autoantibody titers without the broad B cell depletion of rituximab.
Key prediction: ME/CFS patients with elevated serum BAFF (\(>\) 1 ng/mL) receiving belimumab 10 mg/kg IV for 24 weeks show \(\geq 25%\) reduction in autoantibody titers and \(\geq 20%\) improvement in fatigue severity. Falsified if BAFF-normal ME/CFS patients show equivalent or superior response to BAFF-high patients (mechanism would be non-BAFF-mediated).
Limitation: BAFF elevation in ME/CFS is inconsistently reported. Belimumab has not been tested in ME/CFS. Infection risk (opportunistic infections, progressive multifocal leukoencephalopathy risk carries a black box warning). No ME/CFS trial data.
3 Complement C1s Inhibition (Sutimlimab)
(Certainty: 0.35.) IgM is the most potent activator of the classical complement pathway. If IgM-dominant autoantibodies are pathogenic — and complement activation products are documented in ME/CFS — C1s inhibition would prevent complement-mediated tissue injury. Sutimlimab (anti-C1s monoclonal antibody, FDA-approved for cold agglutinin disease — an IgM-mediated condition) blocks C1s proximal to C3 cleavage, preserving alternative and lectin pathway function.
Key prediction: ME/CFS patients with IgM-dominant profiles show elevated classical pathway markers (C4d, sC5b-9) that fall with C1s inhibition, accompanied by improved microvascular function (laser Doppler flowmetry) and reduced orthostatic intolerance. Falsified if complement markers are normal at baseline.
Limitation: Cold agglutinin disease involves a well-defined, single-specificity IgM paraprotein — ME/CFS IgM is polyreactive and its pathogenic role is unproven. No data in ME/CFS. Infection risk from classical pathway blockade (encapsulated bacteria, particularly Neisseria species carry a black box warning). (Tatai et al. 2026).
4 Low-Dose IL-2 Therapy
(Certainty: 0.30.) Treg dysfunction is documented in ME/CFS. Low-dose IL-2 selectively expands CD4\(""^+\)CD25hiFoxP3+ Tregs without activating effector T cells and has shown efficacy in type 1 diabetes and alopecia areata. By restoring Treg-mediated B cell tolerance, low-dose IL-2 could suppress autoantibody production at its regulatory source rather than at downstream effector stages (antibody removal, B cell depletion).
Key prediction: ME/CFS patients with baseline Treg deficiency (less than 5 percent of CD4\(""^+\) T cells) receiving low-dose IL-2 (1 million IU subcutaneously, 5-day cycles) show no less than 50 percent Treg expansion and no less than 15 percent autoantibody reduction at 6 months. Falsified if Treg expansion occurs without autoantibody reduction — suggesting autoantibody production is Treg-independent.
Limitation: No data in ME/CFS. Treg expansion does not guarantee functional restoration (expanded Tregs may be exhausted or incapable of suppressing in an inflammatory milieu). Fever, injection-site reactions.
5 Severity-Stratified Immunomodulatory Protocols
(Certainty: 0.35.) Treatment response heterogeneity in ME/CFS immunomodulation trials — open-label response rates of 47–70% but sham-controlled null results — may reflect unselected patient cohorts with different underlying mechanisms. A severity-stratified and autoantibody-profile-guided treatment algorithm could match patients to interventions:
- Mild–moderate, antibody-positive: Home-based protocol (quercetin, omega-3, vitamin D3, tVNS) — low risk, accessible
- Moderate–severe, IgM-dominant: BTK inhibitor trial enrollment — targets production
- Moderate–severe, IgG-dominant: Immunoadsorption or daratumumab trial enrollment — targets existing antibodies and plasma cells
- Severe–very severe, dual-positive: Combined immunoadsorption + anti-plasma-cell therapy + intensive monitoring — addresses both populations
Rationale for stratification: Different autoantibody profiles predict different dominant antibody production pathways (extrafollicular for IgM, germinal-center-derived for IgG), requiring different therapeutic strategies. Treating all patients with the same protocol — as was done in IA-PACS-CFS (Preßler et al. 2024) — dilutes treatment effects within responsive subgroups.
Implementation requirement: A validated autoantibody panel measuring both GPCR and tissue-specific antibodies (see Section Immunological Biomarkers for the multi-tissue panel proposal) is a prerequisite for stratification. Without such a panel, stratification is speculative. (Tatai et al. 2026).